Publication date: Sep 08, 2025
Limited evidence exists on the additive risk of bradycardia in children with respiratory syncytial virus (RSV) bronchiolitis receiving dexmedetomidine (DMED). We aim to study the association between RSV bronchiolitis and bradycardia during DMED administration. This retrospective cohort study included 273 children under 2 years old admitted to the intensive care units at Boston Children’s Hospital with severe bronchiolitis and sedated with DMED from 2009 to 2022. Children were classified as RSV or non-RSV based on confirmed laboratory results. The primary outcome was a composite measure of clinically significant bradycardia, defined as either a heart rate
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Respiratory Syncytial Virus Infections |
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Dexmedetomidine |
| disease | MESH | bronchiolitis |
| disease | MESH | bradycardia |
Original Article
(Visited 7 times, 1 visits today)